The Incidence and Immunophenotypic and Genetic Features of JL1 Expressing Cells and the Therapeutic Potential of an Anti-JL1 Antibody in De Novo Pediatric Acute Leukemias
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: JL1 is a newly identified CD43 epitope that specifically recognizes leukemic cells. We analyzed the incidence of JL1 expression and compared the clinical, immunophenotypic, and genetic characteristics of de novo pediatric acute leukemia patients with respect to JL1 expression status to determine the therapeutic potential of an anti-JL1 antibody. Methods: Seventy-eight patients with pediatric acute leukemia (52 with ALL, 26 with AML) diagnosed between December 2014 and January 2016 were enrolled prospectively. Flow cytometry for JL1 expression was performed at diagnosis. Clinical, immunophenotypic, and genetic characteristics were compared with respect to JL1 expression status by the Student t-test/Mann–Whitney U test and chi-square test/Fisher’s exact test. Results: The incidence of JL1 expression was 76.9% and 84.6% in ALL and AML patients, respectively. ALL patients with JL1 expression showed higher CD10 and cytoplasmic IgM expressions than those without JL1 expression (P=0.022 and 0.003, respectively) and were associated with TCF3-PBX1 and KMT2A-MLLT1 translocations. AML patients with JL1 expression showed higher CD13 and lower CD65 and CD15 expressions than those without JL1 expression (P=0.013, 0.007, and 0.024, respectively) and were associated with RUNX1-RUNX1T1, PML-RARA, and CBFB-MYH11 translocations. The JL1 expression incidence did not differ between ALL and AML, and the JL1 expression status did not affect prognosis. Conclusions: Our findings support the potential therapeutic role of anti-JL1 monoclonal antibodies; JL1 expression was associated with specific immunophenotypes and genetic abnormalities. Future studies should examine the prognostic impact of JL1 expression in pediatric acute leukemias.
Abstract
Background: JL1 is a newly identified CD43 epitope that specifically recognizes leukemic cells. We analyzed the incidence of JL1 expression and compared the clinical, immunophenotypic, and genetic characteristics of de novo pediatric acute leukemia patients with respect to JL1 expression status to determine the therapeutic potential of an anti-JL1 antibody. Methods: Seventy-eight patients with pediatric acute leukemia (52 with ALL, 26 with AML) diagnosed between December 2014 and January 2016 were enrolled prospectively. Flow cytometry for JL1 expression was performed at diagnosis. Clinical, immunophenotypic, and genetic characteristics were compared with respect to JL1 expression status by the Student t-test/Mann–Whitney U test and chi-square test/Fisher’s exact test. Results: The incidence of JL1 expression was 76.9% and 84.6% in ALL and AML patients, respectively. ALL patients with JL1 expression showed higher CD10 and cytoplasmic IgM expressions than those without JL1 expression (P=0.022 and 0.003, respectively) and were associated with TCF3-PBX1 and KMT2A-MLLT1 translocations. AML patients with JL1 expression showed higher CD13 and lower CD65 and CD15 expressions than those without JL1 expression (P=0.013, 0.007, and 0.024, respectively) and were associated with RUNX1-RUNX1T1, PML-RARA, and CBFB-MYH11 translocations. The JL1 expression incidence did not differ between ALL and AML, and the JL1 expression status did not affect prognosis. Conclusions: Our findings support the potential therapeutic role of anti-JL1 monoclonal antibodies; JL1 expression was associated with specific immunophenotypes and genetic abnormalities. Future studies should examine the prognostic impact of JL1 expression in pediatric acute leukemias.
참고문헌 (17)
- Adams GP, "Monoclonal antibody therapy of cancer", Nat Biotechnol, 23, pp.1147~1157 (2005)
- Gasparini G, "Is tailored therapy feasible in oncology", Crit Rev Oncol Hematol, 57, pp.79~101 (2006)
- Reichert JM, "Monoclonal antibody successes in the clinic", Nat Biotechnol, 23, pp.1073~1078 (2005)
- Cartron G, "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene", Blood, 99, pp.754~758 (2002)
- Weng WK, "Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma", J Clin Oncol, 21, pp.3940~3947 (2003)
- Dall’Ozzo S, "Rituximab-dependent cytotoxicity by natural killer cells : influence of FCGR3A polymorphism on the concentration-effect relationship", Cancer Res, 64, pp.4664~4669 (2004)
- Shin YK, "Expression of leukemia-associated antigen, JL1, in bone marrow and thymus", Am J Pathol, 158, pp.1473~1480 (2001)
- Chung JK, "In vitro and in vivo properties of murine monoclonal antibody for a novel immature thymocyte-differentiated antigen, JL1", Nucl Med Biol, 24, pp.433~437 (1997)
- Park WS, "A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias", Leukemia, 12, pp.1583~1590 (1998)
- Shin YK, "Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications", Cancer Immunol Immunother, 52, pp.506~512 (2003)
- Jeon YK, "Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia", Cancer Immunol Immunother, 60, pp.1697~1706 (2011)
- Scott AM, "Antibody therapy of cancer", Nat Rev Cancer, 12, pp.278~287 (2012)
- Tibes R, "Activity of alemtuzumab in patients with CD52-positive acute leukemia", Cancer, 106, pp.2645~2651 (2006)
- Raetz EA, "Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse : a Children’s Oncology Group Pilot Study", J Clin Oncol, 26, pp.3756~3762 (2008)
- Kantarjian HM, "Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia", N Engl J Med, 375, pp.740~753 (2016)
- Kantarjian H, "Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia", N Engl J Med, 376, pp.836~847 (2017)
- Swerdlow SH, "WHO classification of tumours of hematopoietic and lymphoid tissues" (2016), IARC Press